Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-500
Closed -$2K 3910
2023
Q2
$2K Sell
500
-3,900
-89% -$472K ﹤0.01% 3005
2023
Q1
$15K Sell
4,400
-10,600
-71% -$1.19M ﹤0.01% 2075
2022
Q4
$14K Buy
15,000
+11,700
+355% +$1.28M ﹤0.01% 2461
2022
Q3
$3K Buy
+3,300
New +$279K ﹤0.01% 3933
2022
Q2
Sell
-17,600
Closed -$235K 5113
2022
Q1
$235K Buy
+17,600
New +$1.93M 0.01% 1093
2021
Q4
Sell
-17,600
Closed -$23K 5505
2021
Q3
$23K Buy
+17,600
New +$2.22M ﹤0.01% 3215
2019
Q3
Sell
-6,000
Closed -$49K 4197
2019
Q2
$49K Hold
6,000
﹤0.01% 1554
2019
Q1
$23K Buy
+6,000
New +$211K ﹤0.01% 1942
2018
Q4
Sell
-10,000
Closed -$7K 4074
2018
Q3
$7K Buy
+10,000
New +$310K ﹤0.01% 2851
2017
Q4
Sell
-214,800
Closed -$37K 5100
2017
Q3
$37K Buy
214,800
+85,200
+66% +$1.51M ﹤0.01% 2525
2017
Q2
$48K Buy
129,600
+43,200
+50% +$798K ﹤0.01% 2537
2017
Q1
$75K Buy
86,400
+64,400
+293% +$1.26M ﹤0.01% 2016
2016
Q4
$3K Sell
22,000
-6,400
-23% -$113K ﹤0.01% 5283
2016
Q3
$11K Buy
28,400
+18,000
+173% +$401K ﹤0.01% 4095
2016
Q2
$10K Sell
10,400
-67,600
-87% -$1.15M ﹤0.01% 4115
2016
Q1
$89K Sell
78,000
-74,800
-49% -$1.25M 0.01% 1719
2015
Q4
$28K Buy
+152,800
New +$3.18M ﹤0.01% 3051

Other funds holding DXCM

Cutler Group's DXCM Position: Q1 2024 in Review

Cutler Group sold out of DexCom (DXCM) in Q1 2024, closing a stake of 455 shares — an estimated $57.2K sold.

Cutler Group first reported a position in DXCM in Q1 2016 and held it in 18 quarters. The position peaked at $1.42M in Q3 2021. 1,032 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • Cutler Group reported no remaining DexCom position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 455 DexCom shares in Q1 2024, an estimated $57.2K.
  • Cutler Group first reported a position in DexCom in Q1 2016 and held it in 18 quarters.
  • Cutler Group's DexCom position peaked at $1.42M in Q3 2021.
  • 1,032 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.